新天药业(002873) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was CNY 214,656,599.98, representing a 113.84% increase compared to CNY 100,379,992.91 in the same period last year[8] - Net profit attributable to shareholders reached CNY 25,366,384.98, a significant increase of 714.60% from CNY 3,113,965.50 year-on-year[8] - The net profit after deducting non-recurring gains and losses was CNY 24,867,023.76, up 494.51% from CNY 4,182,758.45 in the previous year[8] - Basic earnings per share rose to CNY 0.2215, marking a 717.34% increase from CNY 0.0271 in the same quarter last year[8] - The company reported a significant increase in other equity instruments from CNY 183,644,362.39 to CNY 233,644,362.39, a rise of approximately 27%[30] - The total comprehensive income for the period was CNY 15,044,870.29, reflecting the same figure as the net profit[44] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 1,525,743,416.24, a slight decrease of 0.66% from CNY 1,535,933,766.56 at the end of the previous year[8] - Total liabilities decreased from CNY 707,636,495.11 to CNY 687,024,626.73, a decrease of approximately 2.9%[31] - Non-current assets increased from CNY 723,053,744.10 to CNY 794,202,565.56, an increase of about 9.8%[30] - Total liabilities decreased to CNY 673,758,824.02 from CNY 701,494,768.15, while total equity increased slightly to CNY 819,848,473.14 from CNY 819,748,469.77[38] - The total assets increased from 1,535,933,766.56 CNY to 1,547,596,915.49 CNY, reflecting an adjustment of 11,663,148.93 CNY[54] Cash Flow - The net cash flow from operating activities was CNY 16,766,677.68, down 52.65% from CNY 35,411,350.35 in the same period last year[8] - The company's net cash flow from investment activities improved by 72.76% to -CNY 65,463,297.81, mainly due to an increase in the redemption of bank wealth management products[15] - The net cash flow from investment activities was -76,595,269.29 CNY, a decrease from -252,781,090.14 CNY year-over-year[51] - The cash inflow from financing activities was 13,000,000.00 CNY, down from 214,800,000.00 CNY in the previous year[51] - The cash outflow for repaying debts was 48,000,000.00 CNY, compared to 25,000,000.00 CNY in the previous year[51] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,517[11] - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., held 38.90% of the shares, with 45,568,962 shares pledged[11] - The company repurchased a total of 3,170,012 shares, accounting for 2.71% of the total share capital, with a total expenditure of CNY 25,498,647.29[19] Expenses - The company's financial expenses surged by 264.26% to CNY 3,787,069.84, primarily due to a decrease in interest subsidies received[15] - The company's research and development expenses decreased by 33.72% to CNY 1,287,534.50, reflecting a reduction in capitalized R&D expenditures[15] - Total operating costs amounted to ¥183,991,577.13, compared to ¥94,727,324.68 in the previous year, reflecting a rise in sales expenses to ¥105,947,606.46 from ¥49,789,784.22[38] Other Financial Metrics - The company received government subsidies amounting to CNY 766,142.44 during the reporting period[9] - The company incurred a credit impairment loss of CNY -780,480.80 during the quarter[46] - The company adjusted its financial statements to comply with new leasing standards, impacting the balance sheet[52] - The first quarter report was not audited, which may affect the reliability of the financial data presented[59]